MyFinsight
Home
Compare
Blog
About
Income Statement
|
Cash Flow
|
Balance Sheet
|
Ratios
|
Compare
Cash Flow Overview
Change in Cash
-$18,913K
Free Cash flow
-$31,961K
Unit: Thousand (K) dollars
Positive Cash Flow Breakdown
Maturities of investments
Accounts payable and accrued oth...
Proceeds from issuance of common...
Others
Negative Cash Flow Breakdown
Purchases of investments
Net loss
Acquisitions of property and equ...
Subscribe for Financial Insights
Page 1
Quarterly
123
Page 1
Cash Flow
2026-06-30
2026-03-31
2025-12-31
2025-09-30
Net loss
-41,492
-35,767
-30,505
-98,963
Depreciation
264
270
320
900
Stock-based compensation expense
7,091
6,898
6,278
18,759
Amortization of premium (accretion of discount) on investments, net
-291
-162
240
2,060
Prepaid expenses and other assets
-21
679
-2,112
325
Accounts payable and accrued other liabilities
2,220
-3,322
-448
-6,798
Net cash used in operating activities
-31,605
-32,438
-22,483
-88,487
Acquisitions of property and equipment
356
2
227
485
Purchases of investments
47,780
77,973
45,289
354,530
Maturities of investments
60,000
60,000
62,500
190,000
Net cash (used in) provided by investing activities
11,864
-17,975
16,984
-165,015
Proceeds from issuance of common stock and pre-funded warrants
0
60,881
0
244,369
Issuance costs associated with financings
0
993
0
2,397
Proceeds from issuance of common stock under espp
679
-
556
757
Proceeds from stock option exercises
149
1,252
944
1,035
Net cash provided by financing activities
828
61,140
1,500
243,764
Net (decrease) increase in cash, cash equivalents and restricted cash
-18,913
10,727
-3,999
-9,738
Cash, cash equivalents and restricted cash at beginning of period
56,887
46,160
76,355
76,355
Cash, cash equivalents and restricted cash at end of period
37,974
56,887
46,160
50,159
Page 1
Unit: Thousand (K) dollars (except for numbers of shares and EPS). Numbers labeled with * are estimated quarterly values.
Page 1
Buy us a coffee
Time Plot
Show the time plot by selecting a row from the table.
Cash Flow
Maturities of investments
$60,000K
Proceeds from issuance of
common stock under espp
$679K
Proceeds from stock
option exercises
$149K
Net cash (used in)
provided by investing...
$11,864K
Net cash provided by
financing activities
$828K
Canceled cashflow
$48,136K
Net (decrease)
increase in cash, cash...
-$18,913K
Canceled cashflow
$12,692K
Stock-based compensation
expense
$7,091K
Accounts payable and
accrued other...
$2,220K
Amortization of premium
(accretion of discount) on...
-$291K
Depreciation
$264K
Prepaid expenses and
other assets
-$21K
Purchases of investments
$47,780K
Acquisitions of property and
equipment
$356K
Net cash used in
operating activities
-$31,605K
Canceled cashflow
$9,887K
Net loss
-$41,492K
Buy us a coffee
Oric Pharmaceuticals, Inc. (ORIC)
Oric Pharmaceuticals, Inc. (ORIC)